Q3 EPS Estimate for Protara Therapeutics Lifted by Analyst

Protara Therapeutics, Inc. (NASDAQ:TARA) – HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for Protara Therapeutics in a note issued to investors on Monday, August 11th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.38) for the quarter, up from their prior forecast of ($0.54). HC Wainwright has a “Buy” rating and a $23.00 price objective on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q4 2025 earnings at ($0.40) EPS, FY2026 earnings at ($1.96) EPS, FY2027 earnings at ($1.98) EPS, FY2028 earnings at ($1.31) EPS and FY2029 earnings at ($0.60) EPS.

Separately, Jones Trading raised Protara Therapeutics to a “strong-buy” rating and set a $21.00 target price on the stock in a report on Thursday, May 22nd. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $19.60.

Protara Therapeutics Stock Down 5.0%

NASDAQ:TARA opened at $3.03 on Thursday. The business’s 50-day simple moving average is $3.11 and its two-hundred day simple moving average is $3.61. The stock has a market cap of $116.90 million, a PE ratio of -1.87 and a beta of 1.42. Protara Therapeutics has a 52 week low of $1.60 and a 52 week high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP purchased a new position in shares of Protara Therapeutics during the fourth quarter valued at approximately $111,000. Bank of America Corp DE boosted its position in shares of Protara Therapeutics by 53,013.9% during the fourth quarter. Bank of America Corp DE now owns 194,397 shares of the company’s stock valued at $1,026,000 after buying an additional 194,031 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Protara Therapeutics during the fourth quarter valued at approximately $802,000. Geode Capital Management LLC boosted its position in shares of Protara Therapeutics by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 179,593 shares of the company’s stock valued at $948,000 after buying an additional 9,553 shares during the period. Finally, Millennium Management LLC boosted its position in shares of Protara Therapeutics by 2,479.2% during the fourth quarter. Millennium Management LLC now owns 371,453 shares of the company’s stock valued at $1,961,000 after buying an additional 357,051 shares during the period. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.